Linked Life Data

20855825

Source:http://linkedlifedata.com/resource/pubmed/id/20855825

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
30
pubmed:dateCreated
2010-10-19
pubmed:abstractText
We compared fulvestrant 500 mg regimen with the approved dose of fulvestrant 250 mg per month for treatment of postmenopausal women with estrogen receptor-positive advanced breast cancer who experienced progression after prior endocrine therapy.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1527-7755
pubmed:author
pubmed:issnType
Electronic
pubmed:day
20
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4594-600
pubmed:dateRevised
2011-9-16
pubmed:meshHeading
pubmed-meshheading:20855825-Antineoplastic Agents, Hormonal, pubmed-meshheading:20855825-Brazil, pubmed-meshheading:20855825-Breast Neoplasms, pubmed-meshheading:20855825-Disease-Free Survival, pubmed-meshheading:20855825-Double-Blind Method, pubmed-meshheading:20855825-Drug Administration Schedule, pubmed-meshheading:20855825-Estradiol, pubmed-meshheading:20855825-Estrogen Antagonists, pubmed-meshheading:20855825-Europe, pubmed-meshheading:20855825-Female, pubmed-meshheading:20855825-Humans, pubmed-meshheading:20855825-Injections, Intramuscular, pubmed-meshheading:20855825-Kaplan-Meier Estimate, pubmed-meshheading:20855825-Logistic Models, pubmed-meshheading:20855825-Middle Aged, pubmed-meshheading:20855825-Odds Ratio, pubmed-meshheading:20855825-Postmenopause, pubmed-meshheading:20855825-Proportional Hazards Models, pubmed-meshheading:20855825-Quality of Life, pubmed-meshheading:20855825-Receptors, Estrogen, pubmed-meshheading:20855825-Risk Assessment, pubmed-meshheading:20855825-Risk Factors, pubmed-meshheading:20855825-Time Factors, pubmed-meshheading:20855825-Treatment Outcome, pubmed-meshheading:20855825-United States
pubmed:year
2010
pubmed:articleTitle
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
pubmed:affiliation
Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy. adileo@usl4.toscana.it
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III